To note, an open-label, dose-escalation/expansion, and multi-center clinical trial (NCT04485013) is enrolling patients with advanced refractory or resistant solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, non-small cell lung cancer, and triple-negative breast cancer, to be given single-agent TTX-080 (anti-HLA-G antibody), or in combination with the PD-1 inhibitor pembrolizumab or the EGFR inhibitor cetuximab. The gene discussed is HLA-G; the disease is triple-negative breast carcinoma.